Department of Clinical and Experimental Medicine, Rheumatology/Division of Neuro and Inflammation Sciences, Linköping University, Linköping, Sweden.
Research and Development, Inova Diagnostics, San Diego, CA, USA.
J Immunol Res. 2018 Aug 30;2018:1294680. doi: 10.1155/2018/1294680. eCollection 2018.
Anti-double-stranded (ds) DNA and anti-C1q autoantibodies are useful tools in the assessment of disease activity and nephritis in systemic lupus erythematosus (SLE) patients. This study aimed to explore the utility of these antibodies along with anti-Ku antibodies in an oligoparametric model approach for the assessment of disease activity and lupus nephritis.
Samples from 261 well-characterized SLE patients were tested using chemiluminescent immunoassays (CIA) for anti-dsDNA and anti-Ku antibodies as well as by anti-C1q antibody ELISA (Inova Diagnostics, USA). Of these SLE patients, 26.4% had lupus nephritis (LN) at the time of blood draw or had a history of LN, and modified SLE disease activity index-2K (SLEDAI) scores were used to assess disease activity.
All three antibodies demonstrated higher prevalence and higher antibody levels in active versus inactive SLE patients and in LN versus non-LN patients. When oligoparametric analysis was performed, the likelihood of LN and patients with active disease increased with dual and triple positivity.
Anti-dsDNA and anti-C1q antibodies are useful tools to identify disease activity and/or renal involvement in SLE patients. In addition, the combination of those antibodies in a two-parametric score might improve the clinical utility of those markers.
抗双链 (ds) DNA 和抗 C1q 自身抗体是评估系统性红斑狼疮 (SLE) 患者疾病活动度和肾炎的有用工具。本研究旨在探索这些抗体与抗 Ku 抗体联合应用于寡参数模型方法评估疾病活动度和狼疮肾炎的效用。
使用化学发光免疫分析 (CIA) 检测 261 例特征明确的 SLE 患者的抗 dsDNA 和抗 Ku 抗体,并通过 Inova Diagnostics(美国)的抗 C1q 抗体 ELISA 进行检测。这些 SLE 患者中,26.4%在采血时或有狼疮肾炎 (LN) 病史时患有 LN,且采用改良 SLE 疾病活动指数-2K (SLEDAI) 评分评估疾病活动度。
在活动期与非活动期 SLE 患者以及 LN 与非 LN 患者中,三种抗体均显示出更高的患病率和更高的抗体水平。进行寡参数分析时,双阳性和三阳性患者发生 LN 和疾病活动的可能性增加。
抗 dsDNA 和抗 C1q 抗体是识别 SLE 患者疾病活动度和/或肾脏受累的有用工具。此外,将这些抗体组合成两个参数评分可能会提高这些标志物的临床实用性。